Yonghua Wang

Mr. Yonghua Wang

Qingdao University

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 May 2024 in Cancer Letters
Verified
Journal Article
Closed access
YYYongbo Yu
Yongbo Yu
YLYe Liang
Ye Liang
FXFei Xie
Fei Xie
ZZZhao Zhang
Zhao Zhang
PZPengfei Zhang
Pengfei Zhang
YWYonghua Wang
Yonghua Wang

5 June 2023 in Molecular Therapy Nucleic Acids
Verified
Journal Article
Open access
GCGuangdi Chu
Guangdi Chu
XJXiaoyu Ji
Xiaoyu Ji
YWYonghua Wang
Yonghua Wang
HNHaitao Niu
Haitao Niu
Muscle-invasive urothelial cancer (MUC), characterized by high aggressiveness and significant heterogeneity, is currently lacking highly precise individualized treatment options. We used a computational pipeline to synthesize multiomics data from MUC patients using 10 clustering algorithms, which were then combined with 10 machine learning algorithms to identify molecular subgroups of high resolution and develop a robust consensus machine learning-driven signature (CMLS). Through multiomics clustering, we identified three cancer subtypes (CSs) that are related to prognosis, with CS2 exhibiting the most favorable prognostic outcome. Subsequent screening enabled identification of 12 hub genes that constitute a CMLS with robust predictive power for prognosis. The low-CMLS group exhibited a more favorable prognosis and greater responsiveness to immunotherapy and was more likely to exhibit the “hot tumor” phenotype. The high-CMLS group had a poor prognosis and lower likelihood of benefitting from immunotherapy, but dasatinib and romidepsin may serve as promising treatments for them. Comprehensive analysis of multiomics data can offer important insights and further refine the molecular classification of MUC. Identification of CMLS represents a valuable tool for early prediction of patient prognosis and for screening potential candidates likely to benefit from immunotherapy, with broad implications for clinical practice.

1 April 2020 in International Immunopharmacology
Verified
Journal Article
Closed access
CSChengquan Shen
Chengquan Shen
JLJing Liu
Jing Liu
JWJirong Wang
Jirong Wang
XZXiulong Zhong
Xiulong Zhong
DDDahai Dong
Dahai Dong
YWYonghua Wang
Yonghua Wang

1 January 2021 in International Immunopharmacology
Verified
Journal Article
Closed access
JWJirong Wang
Jirong Wang
CSChengquan Shen
Chengquan Shen
DDDahai Dong
Dahai Dong
XZXiulong Zhong
Xiulong Zhong
YWYonghua Wang
Yonghua Wang
XYXiaokun Yang
Xiaokun Yang

18 November 2024 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
CLChangxue Liu
Changxue Liu
HGHuaixi Ge
Huaixi Ge
CSChengquan Shen
Chengquan Shen
DHDing Hu
Ding Hu
XZXinzhao Zhao
Xinzhao Zhao
YWYonghua Wang
Yonghua Wang
The biological role and precise molecular mechanisms of Notch receptor 3 (NOTCH3) in the malignant progression of bladder cancer (BLCA) remain unclear. In this study, we found that NOTCH3 was significantly upregulated and associated with poor prognosis in BLCA patients. Functional experiments demonstrated that NOTCH3 knockdown inhibited BLCA cell proliferation, migration, invasion and significantly suppressed tumor growth and metastasis in vivo as well. Mechanically, chromatin immunoprecipitation and dual-luciferase reporter assays confirmed that NOTCH3 could promote the transcription of secreted phosphoprotein 1 (SPP1), a potential downstream target gene of NOTCH3, by binding to the CSL elements in the SPP1 promoter. Moreover, we also found that targeting NOTCH3 inhibited BLCA growth and metastasis by suppressing the SPP1-PI3K/AKT axis. Our study highlights the critical role of NOTCH3-SPP1-PI3K/AKT axis in the malignant progression of BLCA, suggesting that NOTCH3 may be a potential therapeutic target for BLCA.

6 December 2022 in Cell Cycle
Verified
Journal Article
Open access
XZXuezhou Zhang
Xuezhou Zhang
JLJing Liu
Jing Liu
XYXuecheng Yang
Xuecheng Yang
WJWei Jiao
Wei Jiao
CSChengquan Shen
Chengquan Shen
YWYonghua Wang
Yonghua Wang
Extracellular matrix (ECM), as an important framework for tumor microenvironment, plays important roles in many critical processes, including tumor growth, invasion, immune suppression, and drug resistance. However, few biomarkers of ECM-related genes (ERGs) have been developed for prognosis prediction and clinical treatment of bladder cancer (BC) patients. Bioinformatics analysis and LC-MS/MS analysis were used to screen differentially expressed ERGs in BC. Multivariate Cox regression analysis and Lasso regression analysis were used to construct and validate an ERGs-based prognostic prediction model for BC. Immunohistochemistry was used to detect the protein expression of hub gene-COL6A1 in BC patients. Using bioinformatics analysis from The Cancer Genome Atlas (TCGA) database and proteomic analysis from our BC cohort, we constructed and validated an effective prognostic prediction model for BC patients based on four differentially expressed ERGs (MAP1B, FBN1, COL6A1, and MFAP5). Moreover, we identified human collagen VI-COL6A1 was a hub gene in this prognostic prediction model and found that COL6A1 was closely related to malignancy progression, prognosis, and response to PD-1 inhibitor immunotherapy in BC. Our findings highlight the satisfactory predictive value of ECM-related prognostic models in BC and suggested that COL6A1 may be a potential biomarker in predicting malignant progression, prognosis, and efficacy of immunotherapy in BC.